OR WAIT null SECS
January 20, 2020
While the US public and law makers push for price controls, pharma’s venture capitalists have other ideas for balancing innovation and affordability.
January 16, 2020
The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.
January 15, 2020
As the high cost of drugs continues to erode public opinion, experts ask whether price controls are the best, or only, way to improve access to medicines and regain the public’s trust.
January 08, 2020
The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.
January 02, 2020
FDA’s approval rate slowed, but the US agency is still ahead of its international counterparts in green-lighting new drugs for market.
With a positive employment market, some bio/pharma professionals explore options for career advancement.
December 18, 2019
The divestment of the pharma and food ingredients business is in line with Ferrer’s new strategy to focus on the core business of branded pharmaceuticals.
The new scientific advisory board will oversee innovation projects, identify and develop key new technologies, and be responsible for forming high-caliber alliances with innovative start-ups.
December 12, 2019
Under the restructuring, Sanofi will gain sole global rights to Kevzara (sarilumab) and sole ex-US rights to Praluent (alirocumab), while Regeneron will gain sole US rights to Praluent.
December 06, 2019
Expert poll highlights strength of US pharma sector and advances by emerging markets.